MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of avai...
    • Change in fair value of warrant ...
    • Proceeds from exercise of stock ...
    • Non-cash lease expense
Negative Cash Flow Breakdown
    • Purchase of available-for-sale s...
    • Prepaid expenses and other asset...
    • Accounts payable, accrued expens...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-31,630
-39,025
-10,447
-17,459
Non-cash lease expense
85
83
81
79
Accretion of investment discounts
-295
-460
-321
-251
Stock-based compensation
3,154
2,202
2,465
2,428
Change in fair value of warrant liabilities
9,623
18,962
-10,532
-564
Deferred tax provision
-
-
5
-
Prepaid expenses and other assets
1,845
-12
-701
-805
Accounts payable, accrued expenses and other liabilities
-1,681
-4,300
4,038
566
Operating lease liabilities
-88
-86
-81
-81
Net cash used in operating activities
-22,677
-22,612
-14,091
-14,477
Purchase of available-for-sale short-term investments
16,263
43,122
69,223
32,655
Proceeds from maturities of available-for-sale short-term investments
39,500
49,078
48,761
45,060
Net cash provided by investing activities
23,237
5,956
-20,462
12,405
Proceeds from issuances of common stock and pre-funded warrants, net
-
-
53,577
-
Proceeds from exercise of stock options
91
-
115
0
Net cash provided by financing activities
91
-
53,692
0
Net change in cash and cash equivalents
651
-16,656
19,139
-2,072
Cash and cash equivalents at beginning of period
6,152
22,808
3,669
20,549
Cash and cash equivalents at end of period
6,803
6,152
22,808
3,669
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof...$39,500K (-6.76%↓ Y/Y)Proceeds from exercise ofstock options$91K Net cash provided byinvesting activities$23,237K (55.35%↑ Y/Y)Net cash provided byfinancing activities$91K Canceled cashflow$16,263K Net change in cashand cash...$651K (123.63%↑ Y/Y)Canceled cashflow$22,677K Purchase ofavailable-for-sale short-term...$16,263K (-40.65%↓ Y/Y)Change in fair value ofwarrant liabilities$9,623K (143.05%↑ Y/Y)Stock-based compensation$3,154K (17.07%↑ Y/Y)Non-cash lease expense$85K (10.39%↑ Y/Y)Net cash used inoperating activities-$22,677K (-28.02%↓ Y/Y)Canceled cashflow$12,862K Net loss-$31,630K (-78.59%↓ Y/Y)Prepaid expenses andother assets$1,845K (86.55%↑ Y/Y)Accounts payable,accrued expenses and...-$1,681K (-137.17%↓ Y/Y)Accretion of investmentdiscounts-$295K (31.71%↑ Y/Y)Operating leaseliabilities-$88K (-14.29%↓ Y/Y)

Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals, Inc. (ELDN)